Iovance Biotherapeutics, Inc.
IOVA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001425205
No open-market purchases or sales by Iovance Biotherapeutics, Inc. insiders were filed in the last 90 days; 293 institutions reported holding it in 13F filings for Q2 2026, worth $1.19B in total; no superinvestor holds it.
Holders of 5% or more of IOVA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Iovance Biotherapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.50%33.4M shares | +1.10 ppfrom 6.40% | Jul 17, 20252 filings | Jul 28, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
44 Schedule 13D and 13G filings on Iovance Biotherapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 20268:22 AM ET | State Street Corp | 13G | 4.80%21.7M shares | −0.70 ppfrom 5.50%Below 5% | Sep 30, 2026 | SEC |
| Aug 7, 20269:56 AM ET | State Street Corp | 13G | 5.50%24.5M shares | +1.30 ppfrom 4.20% | Jun 30, 2026 | SEC |
| Jul 28, 20264:44 PM ET | BlackRock, Inc. | 13G/A | 7.50%33.4M shares | +1.10 ppfrom 6.40% | Jun 30, 2026 | SEC |
| May 12, 202611:17 AM ET | State Street Corp | 13G | 4.20%17.4M shares | −0.90 ppfrom 5.10%Below 5% | Mar 31, 2026 | SEC |
| Mar 27, 20269:52 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −7.50 ppfrom 7.50%Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 20266:43 AM ET | State Street Corp | 13G | 5.10%20.2M shares | – | Dec 31, 2025 | SEC |
| Jul 29, 20251:46 PM ET | Vanguard Group Inc | 13G/A | 7.50%25.1M shares | – | Jun 30, 2025 | SEC |
| Jul 17, 20258:12 PM ET | BlackRock, Inc. | 13G/A | 6.40%21.3M shares | – | Jun 30, 2025 | SEC |
| May 15, 20254:30 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 3.80%12.8M shares | −3.50 ppfrom 7.30%Below 5% | Mar 31, 2025 | SEC |
| Feb 14, 20254:15 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 7.30%22.1M shares | – | Dec 31, 2024 | SEC |
| Nov 14, 2024 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Oct 18, 2024 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Mar 19, 2024 | Quogue Capital LLC | 13D/AOld format | – | – | – | SEC |
| Mar 1, 2024 | Perceptive Advisors LLC | 13GOld format | – | – | – | SEC |
| Feb 14, 2024 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Point72 Asset Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | MHR Fund Management LLC | 13G/AOld format | – | – | – | SEC |
| Jan 26, 202411:49 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 25, 2024 | State Street Corp | 13G/AOld format | – | – | – | SEC |
| Oct 27, 2023 | Quogue Capital LLC | 13D/AOld format | – | – | – | SEC |
| Feb 17, 2023 | Point72 Asset Management, L.P. | 13GOld format | – | New | – | SEC |
| Feb 14, 2023 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2023 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 6, 2023 | Wellington Management Group LLP | 13G/AOld format | – | – | – | SEC |
| Feb 3, 202312:10 PM ET | BlackRock Inc. | 13GOld format | – | – | – | SEC |
| Feb 2, 2023 | State Street Corp | 13GOld format | – | New | – | SEC |
| Jan 13, 2023 | Quogue Capital LLC | 13D/AOld format | – | – | – | SEC |
| Dec 30, 2022 | MHR Fund Management LLC | 13GOld format | – | New | – | SEC |
| Feb 24, 20225:23 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2022 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 4, 2022 | Wellington Management Group LLP | 13GOld format | – | New | – | SEC |
| Feb 4, 2022 | Franklin Resources Inc | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Perceptive Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Price T Rowe Associates Inc | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Avoro Capital Advisors LLC | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 1, 2021 | Franklin Resources Inc | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20219:57 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Jan 11, 2021 | ARK Investment Management LLCSuperinvestorARK Invest | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
1 notice from officers, directors and other affiliates planning to sell Iovance Biotherapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 20247:11 PM ET | Maynard Ryan DDirector | 50.0K | $503.1K | Nov 12, 2024 | Morgan Stanley Smith Barney LLC Executive Services | SEC |